Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JSKN016 in advanced gastric and gastroesophageal adenocarcinoma
CTR20251582Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN016 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Kanion Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
JSKN016
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20251582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251582.